Big Pharma improves access to medicine

The Big Pharmaceutical companies are slowly improving access of drugs for everyone. After decades of accusations of looking after profits more than the public's health, Big Pharma has taken some positive steps. Some companies are introducing tiered pricing systems that give discounts to poorer nations. They have also been taking steps to give the discounts for a wider range of products.

An annual survey rates how well each pharmaceutical company is doing, and the latest edition has just been released. The Access to Medicine index rakes each company on a range of access issues. Glaxco Smith Kline, Johnson and Johnson and Sanofi rank at the top. you can download the entire report from this link.

Guardian reporter Sarah Boseley has this introduction to the report.   

While British drugmaker GlaxoSmithKline (GSK), whose chief executive Sir Andrew Witty has announced moves to increase access to medicines in the developing world, continues to top the league table, its lead on the rest has shrunk. Two other major pharmaceutical companies, Johnson & Johnson and the vaccine manufacturer Sanofi, are now close behind.

The index ranks 20 leading pharmaceutical companies and is published every two years by the Netherlands-based non-profit Access to Medicines Foundation. It has become an authoritative guide, with input from the World Health Organisation, governments, universities, NGOs and institutional investors.

Drug companies are scored on a range of measures, from their willingness to discount prices in poor countries, to research on neglected diseases of poor people to lobbying, transparency and conduct in clinical trials.

This is the third index and it finds a much greater focus on drug access within drug companies – where it is now often an issue for the board.

"This year's index shows that companies are becoming more organised internally in their approach to access to medicine and that those who do this best tend to perform well across the other aspects we measure. The leaders are really raising the bar," said Wim Leereveld, founder of the index. "It's also clear that companies that do not continue to step up their efforts tend to be overtaken by their peers."

Big Pharm begins to give drugs away

Once accused of being greedy, pharmaceutical companies are increasingly making variations of their drugs available in the under-developed world. AIDS pills that are expensive here in the west, are repackaged in different forms and made available and affordable for the poor.

The companies do this for the good public relations, but they also strike deals with charities that will handle the shipping and distribution costs.

From Bloomberg Businessweek, writers Simeon Bennett and Tom Randall explain the new distribution of drugs into the under-developed world.

Pharmaceutical companies, once blasted as uncaring or downright greedy for charging thousands of dollars for a year's worth of AIDS medicines like Viread in poor countries, lately have been slashing prices and licensing their drugs for free or nominal cost to nonprofits or local manufacturers in the developing world. Activists say the largesse is in part an attempt to avoid a repeat of the public-relations backlash the companies received a decade ago after initially pricing the drugs at levels only patients in the West could widely afford.

Also, a network of aid agencies and local manufacturers is now in place to handle production and distribution of the compounds—something many Western companies don't want to handle themselves because of the cost and transportation hassles. "It's a pretty remarkable" shift, says Mitchell Warren, a New York AIDS activist, noting that 10 years ago drugmakers argued that the infected in Africa couldn't be trusted to properly take complicated drug regimes at any price. Two years ago, Pfizer (PFE) granted a free license to a nonprofit group to develop the company's AIDS drug, Selzentry, for use in another experimental gel. Last month a GlaxoSmithKline (GSK) affiliate said it will give away licenses to some of the AIDS drugs it's developing in 60 of the world's least-developed nations where 80 percent of people with HIV live.

At the AIDS meeting in Vienna, Unitaid, another nonprofit, said it is discussing the creation of a "patent pool" with Gilead, Merck (MRK), and Johnson & Johnson (JNJ) to license drugs in development to generic makers who could sell medicines at lower prices than possible for the large companies. "We're talking about the how rather than the whether" companies will participate, said Ellen 't Hoen, Unitaid's executive director.